Bovie Medical Corporation revised earnings guidance for the full year 2017. For the year, the company expects total revenue in the range of $37.0 million to $37.5 million, representing growth of 0% to 1% year-over-year, compared to prior guidance which assumed growth in the range of approximately 4% to 5% year-over-year. The change in the total revenue guidance range is driven primarily by softer sales performance in the company core segment in the fourth quarter. The company expects a GAAP net loss of approximately $6.3 million, compared to prior guidance for a loss of $5 million and adjusted EBITDA loss in a range of $4.6 million to $4.8 million, compared to adjusted EBITDA loss in a range of $3.3 to $3.5 million previously. The new GAAP net loss and adjusted EBITDA loss range for fiscal year 2017 includes approximately $0.9 million in separation expense related to the CEO change.